[go: up one dir, main page]

WO2007049089A8 - Utilisation de ga et de nif pour traiter des tissus ischemiques ou endommages - Google Patents

Utilisation de ga et de nif pour traiter des tissus ischemiques ou endommages

Info

Publication number
WO2007049089A8
WO2007049089A8 PCT/IB2005/003202 IB2005003202W WO2007049089A8 WO 2007049089 A8 WO2007049089 A8 WO 2007049089A8 IB 2005003202 W IB2005003202 W IB 2005003202W WO 2007049089 A8 WO2007049089 A8 WO 2007049089A8
Authority
WO
WIPO (PCT)
Prior art keywords
myocardium
regeneration
blood vessels
damaged tissues
stimulating growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/003202
Other languages
English (en)
Other versions
WO2007049089A1 (fr
Inventor
Ming Li
Lei Cheng
Xin-Sheng Yao
Hong-Wei Liu
John Elsby Sanderson
Xue-Mei Gu
Leonard Wing-Hong Cheung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lead Billion Ltd
Original Assignee
Lead Billion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Billion Ltd filed Critical Lead Billion Ltd
Priority to PCT/IB2005/003202 priority Critical patent/WO2007049089A1/fr
Priority to EP06805090.5A priority patent/EP1848440B1/fr
Priority to HK08105212.3A priority patent/HK1110784B/xx
Priority to CA2593161A priority patent/CA2593161C/fr
Priority to JP2008529455A priority patent/JP5117386B2/ja
Priority to PCT/CN2006/002885 priority patent/WO2007048352A1/fr
Priority to US11/722,911 priority patent/US20080124388A1/en
Priority to ES06805090T priority patent/ES2427354T3/es
Priority to US11/722,915 priority patent/US9155744B2/en
Priority to EP06805091.3A priority patent/EP1848445B1/fr
Priority to PCT/CN2006/002886 priority patent/WO2007048353A1/fr
Priority to ES06805091.3T priority patent/ES2540912T3/es
Priority to JP2008529456A priority patent/JP4950996B2/ja
Priority to AU2006308338A priority patent/AU2006308338B2/en
Priority to DK06805091.3T priority patent/DK1848445T3/en
Priority to AU2006308337A priority patent/AU2006308337B2/en
Priority to CA2593171A priority patent/CA2593171C/fr
Priority to HK08108022.7A priority patent/HK1112848B/xx
Priority to DK06805090.5T priority patent/DK1848440T3/da
Priority to CN2006800018615A priority patent/CN101137387B/zh
Priority to CN2006800018634A priority patent/CN101141965B/zh
Publication of WO2007049089A1 publication Critical patent/WO2007049089A1/fr
Publication of WO2007049089A8 publication Critical patent/WO2007049089A8/fr
Anticipated expiration legal-status Critical
Priority to US13/517,600 priority patent/US20120252744A1/en
Priority to US14/843,898 priority patent/US20160058797A1/en
Priority to US15/380,659 priority patent/US20170095495A1/en
Priority to US15/462,626 priority patent/US20170189432A1/en
Priority to US16/398,026 priority patent/US20190358251A1/en
Priority to US16/409,511 priority patent/US20200101096A1/en
Priority to US17/070,881 priority patent/US20210268010A1/en
Priority to US17/456,763 priority patent/US20220152070A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Après un infarctus du myocarde, le myocarde est incapable de générer de nouveaux cardiomyocytes permettant de remplacer les cellules musculaires perdues. Des tissus cicatriciels, qui remplacent le myocarde nécrosé, peuvent dégrader encore davantage la fonction cardiaque. Il n'existe aucun médicament efficace susceptible de stimuler la croissance de nouveaux vaisseaux sanguins (angiogenèse) à un stade précoce. Il est avéré qu'un extrait organique d'une variante de Geum Japonicum Thumb stimule la croissance de vaisseaux sanguins fonctionnels et/ou régénère le myocarde dans des tissus endommagés, en particulier dans des tissus cardiaques endommagés, mais les composés exacts qui sont responsables de ces fonctions ne sont pas connus. La présente invention identifie ainsi deux composés, Gémine A et Niga-ichigoside F1, qui ont pour activité de stimuler la croissance de vaisseaux sanguins fonctionnels et/ou la régénération du myocarde dans des tissus endommagés.
PCT/IB2005/003202 2005-10-27 2005-10-27 Utilisation de ga et de nif pour traiter des tissus ischemiques ou endommages Ceased WO2007049089A1 (fr)

Priority Applications (29)

Application Number Priority Date Filing Date Title
PCT/IB2005/003202 WO2007049089A1 (fr) 2005-10-27 2005-10-27 Utilisation de ga et de nif pour traiter des tissus ischemiques ou endommages
CA2593171A CA2593171C (fr) 2005-10-27 2006-10-27 Composition pharmaceutique et procede de neoangiogeneses/revascularisation utilise dans le traitement de maladies cardiaques ischemiques
AU2006308337A AU2006308337B2 (en) 2005-10-27 2006-10-27 Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries
CA2593161A CA2593161C (fr) 2005-10-27 2006-10-27 Composition pharmaceutique et procede de regeneration de myofibres dans le traitement de lesions musculaires
JP2008529455A JP5117386B2 (ja) 2005-10-27 2006-10-27 筋傷害の治療における筋線維の再生のための医薬組成物及び方法
PCT/CN2006/002885 WO2007048352A1 (fr) 2005-10-27 2006-10-27 Composition pharmaceutique et procede de regeneration de myofibres dans le traitement de lesions musculaires
US11/722,911 US20080124388A1 (en) 2005-10-27 2006-10-27 Pharmaceutical Composition And Method For Neoangiogenesis/Revascularization Useful In Treating Ischemic Heart Diseases
ES06805090T ES2427354T3 (es) 2005-10-27 2006-10-27 Composición farmacéutica y método para regenerar miofibras en el tratamiento de lesiones musculares
US11/722,915 US9155744B2 (en) 2005-10-27 2006-10-27 Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries
HK08108022.7A HK1112848B (en) 2005-10-27 2006-10-27 Pharmaceutical composition for regenerating myofibers in the treatment of muscle injuries
PCT/CN2006/002886 WO2007048353A1 (fr) 2005-10-27 2006-10-27 Composition pharmaceutique et procede de neoangiogeneses/revascularisation utilise dans le traitement de maladies cardiaques ischemiques
ES06805091.3T ES2540912T3 (es) 2005-10-27 2006-10-27 Composición farmacéutica y método de neoangiogénesis/revascularización útiles en el tratamiento de enfermedades cardíacas isquémicas
JP2008529456A JP4950996B2 (ja) 2005-10-27 2006-10-27 虚血性心疾患の治療に有用な、血管新生／血行再建のための医薬組成物及び方法
AU2006308338A AU2006308338B2 (en) 2005-10-27 2006-10-27 Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases
DK06805091.3T DK1848445T3 (en) 2005-10-27 2006-10-27 Pharmaceutical composition and method of neoangiogenesis / revascularization useful in the treatment of ischemic heart disease
EP06805090.5A EP1848440B1 (fr) 2005-10-27 2006-10-27 Composition pharmaceutique et procede de regeneration de myofibres dans le traitement de lesions musculaires
DK06805090.5T DK1848440T3 (da) 2005-10-27 2006-10-27 Farmaceutisk sammensætning og fremgangsmåde til regenerering af myofibre i behandlingen af muskelskader
EP06805091.3A EP1848445B1 (fr) 2005-10-27 2006-10-27 Composition pharmaceutique et procede de neoangiogeneses/revascularisation utilise dans le traitement de maladies cardiaques ischemiques
HK08105212.3A HK1110784B (en) 2005-10-27 2006-10-27 Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases
CN2006800018615A CN101137387B (zh) 2005-10-27 2006-10-27 可用于治疗缺血性心脏病的新血管生成/再血管化的药物组合物和方法
CN2006800018634A CN101141965B (zh) 2005-10-27 2006-10-27 用于在肌肉损伤治疗中使肌纤维再生的药物组合物
US13/517,600 US20120252744A1 (en) 2005-10-27 2012-06-14 Pharmaceutical Composition and Method for Neoangiogenesis/Revascularization Useful in Treating Ischemic Heart Disease
US14/843,898 US20160058797A1 (en) 2005-10-27 2015-09-02 Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries
US15/380,659 US20170095495A1 (en) 2005-10-27 2016-12-15 Pharmaceutical Composition and Method for Neoangiogenesis/Revascularization Useful in Treating Ischemic Heart Disease
US15/462,626 US20170189432A1 (en) 2005-10-27 2017-03-17 Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries
US16/398,026 US20190358251A1 (en) 2005-10-27 2019-04-29 Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries
US16/409,511 US20200101096A1 (en) 2005-10-27 2019-05-10 Pharmaceutical Composition and Method for Neoangiogenesis/Revascularization Useful in Treating Ischemic Heart Disease
US17/070,881 US20210268010A1 (en) 2005-10-27 2020-10-14 Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart disease
US17/456,763 US20220152070A1 (en) 2005-10-27 2021-11-29 Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2005/003202 WO2007049089A1 (fr) 2005-10-27 2005-10-27 Utilisation de ga et de nif pour traiter des tissus ischemiques ou endommages

Publications (2)

Publication Number Publication Date
WO2007049089A1 WO2007049089A1 (fr) 2007-05-03
WO2007049089A8 true WO2007049089A8 (fr) 2007-09-13

Family

ID=36218724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/003202 Ceased WO2007049089A1 (fr) 2005-10-27 2005-10-27 Utilisation de ga et de nif pour traiter des tissus ischemiques ou endommages

Country Status (2)

Country Link
CN (1) CN101141965B (fr)
WO (1) WO2007049089A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007048352A1 (fr) 2005-10-27 2007-05-03 Lead Billion Limited Composition pharmaceutique et procede de regeneration de myofibres dans le traitement de lesions musculaires
AU2010258351B2 (en) 2009-06-12 2015-05-21 Generex Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of heart failure
CN106565814A (zh) * 2010-12-23 2017-04-19 沪亚生物国际有限责任公司 纯化的心肌生成素异构体及相关方法
CN102499932B (zh) * 2011-11-04 2013-03-06 中国人民武装警察部队后勤学院 野蔷薇苷在制备抗缺氧药物中的应用
CN103193855B (zh) * 2013-04-02 2015-07-29 沈阳化工大学 一种金樱子皂苷单体的制备方法
US20200085875A1 (en) * 2017-04-20 2020-03-19 North Carolina State University Platelet vesicle-engineered cells for targeted tissue repair
CN114028459A (zh) * 2021-11-11 2022-02-11 杭州科贝生物制药有限公司 预防和治疗哺乳动物缺血性心脏病的药物和制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916919A (en) * 1997-06-27 1999-06-29 Dalhousie University Retrovirus protease inhibitors
ES2353378T3 (es) * 2001-11-21 2011-03-01 The Chinese University Of Hong Kong Composiciones que comprenden extractos orgánicos de geum japonicum var. thunb y el uso de las mismas.
EP1569668B1 (fr) * 2002-12-10 2011-07-20 Lead Billion Limited Extrait organique d'une variante de geum japonicum thunb et son utilisation

Also Published As

Publication number Publication date
WO2007049089A1 (fr) 2007-05-03
CN101141965B (zh) 2011-01-26
CN101141965A (zh) 2008-03-12

Similar Documents

Publication Publication Date Title
CY2018026I1 (el) Χρηση στρωματικων βλαστοκυτταρων λαμβανομενων απο λιπωδη ιστο στην θεραπεια συριγγιου
WO2007134126A3 (fr) Appareils chargeurs différés, trousses correspondantes et méthodes pour leur utilisation
WO2007035843A3 (fr) Procédés et compositions pour fonctionnalité d'organes et de tissus
WO2006044467A3 (fr) Procede et dispositif destines a une reconstruction percutanee du ventricule gauche
WO2005094553A3 (fr) Procedes pour executer des procedures medicales favorisant la croissance osseuse, procedes de fabrication de compositions favorisant la croissance osseuse, et appareil pour de tels procedes
WO2008019116A3 (fr) Appareil médical implantable avec revêtement particulaire
EP2197270B8 (fr) Greffons de tissu placentaire et procédés améliorés pour leur préparation et leur utilisation
IL190565A (en) Transplantation facility for endovascular repair and repair of defects in space and tissues
WO2006118801A3 (fr) Dispositifs d'implants medicaux polyvalents
WO2005065418A3 (fr) Compositions et procedes d'utilisation de peptides de ciblage pour le diagnostic et la therapie
WO2009022907A3 (fr) Procédé d'identification, d'expansion et de retrait de cellules souches adultes et de cellules souches cancéreuses
WO2008005888A3 (fr) Dispositifs et procédés d'athérectomie
EP1933715A4 (fr) Systeme et procede permettant de caracteriser un tissu vasculaire
WO2006026730A3 (fr) Tissus tridimensionnels de culture et utilisations de ceux-ci
WO2007046989A3 (fr) Appareil et procedes d'elimination selective de tissus a l'aide de combinaisons d'energie ultrasonore et d'energie cryogenique
WO2009117435A3 (fr) Dispositifs et procédés d’accès percutané, d’hémostase, et de fermeture
WO2008103781A3 (fr) Dispositif pour traiter le rachis
GB0504988D0 (en) Device and method for the treatment of diseased tissue such as tumors
EP1824414A4 (fr) Compositions, systemes et procedes pour le traitement d'anomalies dans des vaisseaux sanguins
WO2006096793A3 (fr) Implants medicaux
EP2061548A4 (fr) Appareil et procédés d'administration de cellules souches et d'autres agents à un tissu cardiaque
WO2011011482A3 (fr) Composition de greffon tissulaire à densité variable et procédés de préparation et d'utilisation de cette composition
WO2007008983A3 (fr) Systemes et procedes de realisation de protheses
WO2008011524A3 (fr) Procédé d'utilisation de cellules souches mitotiquement inactivées pour la réparation de tissus endommagés
WO2007049089A8 (fr) Utilisation de ga et de nif pour traiter des tissus ischemiques ou endommages

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05801768

Country of ref document: EP

Kind code of ref document: A1